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Abstract
Objective
Stent implantation into atherosclerotic coronary vessels impacts on downstreammicrovas-
cular function and induces the release of particulate debris and soluble substances, which
differs qualitatively and quantitatively between native right coronary arteries (RCAs) and sa-
phenous vein grafts on right coronary arteries (SVG-RCAs). We have now quantified the re-
lease of microparticles (MPs) during stent implantation into stable atherosclerotic lesions
and compared the release between RCAs and SVG-RCAs.
Methods
In symptomatic, male patients with stable angina and a stenosis in their RCA or SVG-RCA,
respectively (n = 14/14), plaque volume and composition were analyzed using intravascular
ultrasound before stent implantation. Coronary aspirate was retrieved during stent implanta-
tion with a distal occlusion/aspiration device and divided into particulate debris and plasma.
Particulate debris was weighed. Platelet-derived MPs (PMPs) were distinguished by flow
cytometry as CD41+, endothelium-derived MPs (EMPs) as CD144+, CD62E+ and CD31+/
CD41-, leukocyte-derived MPs as CD45+, and erythrocyte-derived MPs as CD235+.
Results
In patients with comparable plaque volume and composition in RCAs and SVG-RCAs, intra-
coronary PMPs and EMPs were increased after stent implantation into their RCAs and
SVG-RCAs (CD41+: 2729.6±645.6 vs. 4208.7±679.4 and 2355.9±503.9 vs. 3285.8±733.2
nr/µL; CD144+: 451.5±87.9 vs. 861.7±147.0 and 444.6±74.8 vs. 726.5±136.4 nr/µL;
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CD62E+: 1404.1±247.7 vs. 1844.3±378.6 and 1084.6±211.0 vs. 1783.8±384.3 nr/µL,
P<0.05), but not different between RCAs and SVG-RCAs.
Conclusion
Stenting in stable atherosclerotic lesions is associated with a substantial release not only of
PMPs, but also of EMPs in RCAs and SVG-RCAs. Their release does not differ between
RCAs and SVG-RCAs.
Trial Registration
ClinicalTrials.gov NCT01430884
Introduction
Stent implantation into an atherosclerotic lesion induces a traumatic plaque rupture and the
release of particulate debris as well as of soluble vasomotor, thrombogenic, and inflammatory
substances [1–4]. Both, the released particulate debris and the soluble substances contribute to
impaired microvascular coronary perfusion [5–7]. The underlying atherosclerosis in native
coronary arteries differs from that in SVGs, which is more rapidly progressing [8,9]. In patients
with similar plaque volume and composition, stent implantation releases less particulate debris
in native right coronary arteries (RCAs) than in SVGs on right coronary arteries (SVG-RCAs)
[3].
Microparticles (MPs) are anucleoid phospholipid vesicles with a diameter between 0.1–
1 μm. MPs are to be distinguished from smaller exosomes (0.04–0.1 μm), which originate from
the endoplasmic membranes, and from larger phospholipid vesicles, the apoptotic bodies
(>1.5 μm), which contain nuclear material [10]. MPs are shedded from plasma membranes of
diverse source cells (endothelial cells and various blood cells, including platelets, leukocytes,
and erythrocytes) [11,12] in response to various stimuli such as apoptosis [13], platelet activa-
tion [14], inflammatory cytokines e.g. tumor necrosis factor (TNF)α [15], and shear stress [16].
MPs contain a spectrum of bioactive molecules such as chemokines, cytokines, functional
mRNAs and miRNAs, growth factors, and membrane receptors [11,17]. Platelet-derived MPs
(PMPs) act as a source of vasoconstrictor thromboxane A2 and participate in thrombus forma-
tion and leukocyte adhesion [18]. Endothelium-derived MPs (EMPs) contribute also to im-
paired vasodilation [19].
MPs have been identified in human atherosclerotic plaques [20,21] and are increased in pe-
ripheral venous blood of patients with stable coronary artery disease (CAD) [12]. During a
spontaneous plaque rupture in native coronary arteries i.e. in ST-elevation myocardial infarc-
tion (STEMI) the release of MPs in coronary blood was further increased [22–24] suggesting
that plaque rupture and platelet activation might be a trigger/stimulus for MP formation. Res-
toration of epicardial blood flow led to reduction of intracororonary EMPs and PMPs [19,20]
in this acute setting. MPs might serve not only as an index or marker of platelet activation or
vascular injury, but also as a trigger of microvascular obstruction in patients with reperfused
STEMI [25].
Whether or not a traumatic plaque rupture induced by a stent implantation into stable ath-
erosclerotic lesions also induces a release of intracoronary EMPs and PMPs is not known. In
the present study, we focused on patients with stable CAD undergoing elective stent implanta-
tion into stenotic RCAs or SVG-RCAs. We analyzed plaque volume and composition by
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intravascular ultrasound (IVUS) [6] before stent implantation. Stent implantation was done
under protection with a distal occlusion/aspiration device, allowing us to capture the total re-
leased MPs into coronary blood during the traumatic plaque rupture. In the aspirated coronary
blood we quantified the release of MPs and compared it between RCAs and SVG-RCAs.
Methods
Materials
Phycoerythrin (PE)-conjugated mouse anti-human cluster of differentiation (CD)144 anti-
body, fluoresceine isothiocyanate (FITC)-conjugated monoclonal mouse anti-human CD235
(glycoforin) antibody, PE-conjugated monoclonal mouse anti-human CD45 antibody were
purchased from Beckman Coulter (Krefeld, Germany). FITC-conjugated monoclonal anti-tis-
sue factor (TF) antibody was from Sekisui Diagnostics (Stamford, CT, USA). PE-conjugated
mouse anti human CD62E, PE-conjugated mouse anti-human CD31 and PE-Cy5-conjugated
mouse anti-human CD41 antibodies were from Beckton Dickinson Pharmingen (Heidelberg,
Germany). Microbead standards were from Polyscience Inc. (Eppelheim, Germany), Accu-
Check counting beads were purchased from Life Technologies (Darmstadt, Germany).
Ethics Statement
The local institutional review board (Ethik-Kommission der Medizinischen Fakultät der Uni-
versität Duisburg-Essen; Germany, GZ.: 07–3387) approved this observational study. With pa-
tients’ written informed consent, we analyzed the coronary blood from symptomatic male
patients with stable angina pectoris and with a stenosis in their RCAs or SVG-RCAs undergo-
ing stent implantation under the use of a distal occlusion/aspiration device. We here respective-
ly analyzed available aspirated coronary blood samples, which were leftovers from other prior
studies [1,3,4,26,27]. Respective patients with a stenosis in their RCAs (n = 14) or SVG-RCAs
(n = 14) were enrolled between March 2010 and May 2013. The study was conducted in accor-
dance with the ethical guidelines of the Declaration of Helsinki 1975, and registered at Clinical-
Trials.gov (ClinicalTrials.gov Identifier: NCT01430884).
Quantitative coronary angiography
All patients were on oral aspirin (100 mg/day). Thirteen patients with RCA stenosis and 14 pa-
tients with SVG-RCA stenosis were also on oral clopidogrel (75 mg/day) prior to the interven-
tion, for indications such as prior stent implantation or acute coronary syndromes within a
year prior to the current study. After additional loading with clopidogrel (600 mg, oral) and
heparin (10.000 I.U., i.v.), coronary angiography was performed using the femoral approach
and 6 F or 8 F guiding catheters [1–4]. Stenosis severity was quantified using off-line caliper
measurements (QCA-MEDIS, Leiden, NL) [28], and thrombolysis in myocardial infarction
(TIMI) flow was measured before and after stent implantation [29].
IVUS and virtual histology (VH)
IVUS was performed before and after stent implantation with a commercial catheter (Eagle-
EyeTM 20 MHz Volcano Corporation, Rancho Cordova, CA, USA) and pullback device
(0.05 mm/s, R-100, Volcano Corporation, Rancho Cordova, CA, USA). The site and length of
the target lesion were retrospectively identified after stent implantation from landmarks in the
vascular profile [1,30]. The plaque composition was categorized with VH using customized
software (pcVHTM2.1, Volcano Corp.). Plaque components (fibrotic, fibro-fatty, necrotic
core, dense calcium) were presented as a fraction of total plaque volume (%) [1,31].
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Interventional procedure
The implantation of balloon-expandable bare metal stents was performed with direct stenting
and without prior dilatation/debulking using a stent-to-vessel diameter ratio of 1:1.15, because
stenting with prior dilatation increases plaque mobilisation and debris embolism [32]. To pre-
vent coronary microembolization, a distal balloon occlusion/aspiration device (GuardWire
Temporary Occlusion & Aspiration System; Medtronic Inc., Minneapolis, MN USA) [33] was
used. Before stent implantation, the balloon of the device was inflated at 2–4 atm with contrast
agent. After stent implantation, the balloon catheter was removed, and the aspiration catheter
loaded on the wire-balloon. During slow withdrawal of this catheter, the blood column was re-
trieved. Then, the distal wire-balloon was deflated [1–4].
Coronary arterial blood and aspirate
Coronary arterial blood was taken through the aspiration catheter (10 mL into Heparin
S-Monovette, SARSTEDT AG & Co, Nümbrecht, Germany) distal to the lesion before the stent
implantation and served as control. Coronary aspirate (between 10 and 20 mL) was filtered ex
vivo through a 40 μmmesh filter. The aspirate dilution by contrast agent was corrected for by
reference to the hematocrit [1–4]. The released particulate debris was retained on the filter and
weighed. The filtered coronary arterial and aspirate samples were immediately centrifuged
(800 g, 10 min). Platelet-free plasma was obtained by two centrifugations of the plasma samples
(10000 g, 5 min, each). Plasma and platelet-free plasma were quickly frozen in liquid nitrogen
and stored at -80°C until further use.
Tissue factor (TF), TNFα, and troponin I
We determined the plasma concentration of TF and compared it with the number of TF-bear-
ing MPs; TNFα - as a potential trigger for MP release—was determined in coronary arterial
and aspirate plasma using enzyme immunometric assay kits (American diagnostica inc, Stam-
ford, USA for tissue factor; Cayman Chemical Company, Ann Arbor, USA for TNFα) [1].
Peripheral venous blood was taken before and between 6 and 48 h after stent implantation
to determine serum troponin I [1,27]. Serum troponin I was measured using a specific 2-side
immunoassay detected with the Dimension RxL Max Integrated Chemistry System (Siemens
Healthcare Diagnostics, Eschborn, Germany).
Characterization of MP subpopulations by flow cytometry
MP subpopulations were distinguished by flow cytometry according to the expression of estab-
lished surface antigens, as described previously [34]. Briefly, platelet-free plasma samples were
incubated for 30 min with fluorochrome-labeled antibodies or matching isotype controls and
analyzed in a FACSVerse flow cytometer (Beckton Dickinson, Heidelberg, Germany). MP size
was demarcated from particles with smaller size (exosomes) and larger size (apoptotic bodies).
The threshold of 0.2 μmwas set the technical inability of the flow cytometer to detect particles
<0.2 μm [35], realizing that MPs with a size between 0.1–0.2 μmwere not accounted for in this
way. The microbead standard of 1.0 μm was used as upper limit. The total number of MPs was
quantified and the homogeneity of the sample verified by addition of an internal counting stan-
dard with two fluorospheres (30 μL AccuCheck counting beads with 30300 beads) to each sam-
ple (300 μL). The detected numbers of both fluorosphere beads were compared with numbers
provided by the manufacture. The counted MP number per μL was normalized to the fluoro-
sphere beads and expressed as number(nr)/μL. The MP subpopulations were defined as fol-
lows: platelet-derived MPs (PMPs) were defined as CD41+, endothelium-derived MPs (EMPs)
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as CD144+, CD62E+ or CD31+/CD41-, leukocyte-derived MPs (LMPs) as CD45+, and erythro-
cyte-derived MPs (ERMPs) as CD235+. TF-bearing MPs were defined as MPs positive for TF
antibody corrected by isotype background.
Statistical analysis
Continuous data are presented as mean±standard error of the mean (SEM), categorical data as
absolute numbers. Patient characteristics were compared using unpaired t test (continuous
data) and 2-tailed Fisher’s exact test (categorical data). TF plasma concentration and the num-
ber of MPs in coronary arterial and aspirate plasma were additionally presented in a box plot
as minimum and maximum (crosses), interquartile range from 25 to 75% (box), mean
(square), and median (line). Data for serum troponin I before and after stent implantation, TF
and TNFα plasma concentrations, and the number of MPs in coronary arterial and aspirate
plasma were analyzed by a 2-way repeated measures ANOVA followed by Fisher’s LSD post-
hoc tests. Differences were considered significant at the level of p<0.05. The statistics were
done with SigmaStat, Systat software Inc., San Jose, USA.
Results
Patient characteristics, volume and composition of plaques
Patients with stenotic RCA and SVG-RCA, respectively, had comparable characteristics, apart
from their target vessel, minimal lumen area, reference lumen area, and stent diameter (Tables
1 and 2). In both groups, TIMI flow was higher after stent implantation, but not different be-
tween groups. Serum troponin I was increased after stent implantation and also not different
between groups (Table 3). However, the increase in troponin I after stent implantation under
protection with an aspiration device was modest and exceeded the proposed cut off level of
0.15 μg/L, reflecting myonecrosis [36], in only 5 patients with stent implantation into RCA and
4 patients with stent implantation into SVG-RCA, respectively.
Volume and composition of plaques and particulate debris
Plaque volume and composition were comparable between patients with a stenotic RCA and
a stenotic SVG-RCA (Fig 1). The amount of released particulate debris from RCA was less than
that from SVG-RCA, even when normalized to stent volume (0.30±0.09 vs. 0.87±0.17 mg/mm3,
P<0.05).
TF, TF-bearing MP, and TNFα in coronary aspirate
The plasma concentration of TF was not altered after stent implantation and not different between
RCA and SVG-RCA (RCA: 7.2±0.6 vs. 7.0±0.8 pmol/L; SVG-RCA: 7.5±0.6 vs. 7.9±0.4 pmol/L,
P<0.05). The number of TF-bearing MPs was also not altered after stent implantation within both
groups and not different between groups (RCA: 1140.1±274.3 vs. 1148.1±339.6 nr/μL; SVG-RCA:
1155.6±207.3 vs. 1122.4±280.2 nr/μL, P<0.05) (Fig 2). The concentration of TNFα was increased
after stent implantation in RCA and SVG-RCA (RCA: 0.4±0.05 vs. 1.7±0.3 pmol/L; SVG-RCA:
0.4±0.05 vs. 1.9±0.3 pmol/L, P<0.05), but not different between groups.
MP in coronary aspirate
The number of PMPs (CD41+) was increased after stent implantation in both groups, but not
different between groups (RCA: 2729.6±645.6 vs. 4208.7±679.4 nr/μL; SVG-RCA: 2355.9±
503.9 vs. 3285.8±733.2 nr/μL, P<0.05). The numbers of CD144+ and CD62+ were increased
Intracoronary Microparticle Release
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Table 1. Patient characteristics.
RCA SVG-RCA P-value
demographics
number 14 14 1.0
gender, female/male 0/14 0/14 1.0
age [years] 58±3 64±3 0.2
body height [cm] 176±2 176±2 0.9
body weight [kg] 87±4 85±2 0.8
risk factors/comorbities
hypertension 14 14 1.0
BMI [kg/m2] 28.1±1.4 27.4±0.7 0.7
smoking 7 3 0.2
diabetes mellitus 7 6 1.0
hypercholesterolemia 13 14 1.0
family history of CAD 6 5 1.0
hemodynamics
systolic blood pressure [mmHg] 129±7 130±7 0.9
diastolic blood pressure [mmHg] 71±4 66±3 0.3
heart rate [bpm] 63±3 67±3 0.3
laboratory analysis
erythrocytes [*1012/L] 4.5±0.2 4.6±0.1 0.7
leukocytes [*109/L] 7.4±0.5 7.1±0.5 0.9
platelets [*109/L] 226.2±19.8 212.2±12.6 0.5
total cholesterol [mmol/L] 5.0±0.3 4.4±0.3 0.2
HDL cholesterol [mmol/L] 1.1±0.1 1.0±0.1 0.5
LDL cholesterol [mmol/L] 3.2±0.3 2.5±0.2 0.1
triglycerides [mmol/L] 2.2±0.3 2.4±0.4 0.6
serum creatinine [μmol/L] 145.2±30.4 136.4±34.1 0.8
urea nitrogen [mmol/L] 7.7±0.9 7.5±1.2 0.9
eGFR [mL/min/1.73 m2] 60.0±6.3 64.2±5.3 0.6
HbA1c [%] 6.6±0.4 7.1±0.6 0.5
medication
ACE inhibitors 9 11 0.7
AT1-receptor antagonists 2 1 1.0
beta-blockers 12 13 1.0
calcium antagonists 4 1 0.3
statins 13 14 1.0
diuretics 5 9 0.3
antidiabetics 6 6 1.0
insulin 1 0 1.0
aspirin 14 14 1.0
clopidogrel 13 14 1.0
Continuous data are presented as mean±SEM, categorical data as absolute numbers. Comparison between patients with RCA and with SVG-RCA by
unpaired t test (continuous data) and 2-tailed Fisher’s exact test (categorical data). ACE = angiotensin-converting enzyme; AT1 = angiotensin II type 1;
BMI = body mass index; bpm = beats per minute; CAD = coronary artery disease; eGFR = estimated glomerular ﬁltration rate; HbA1c = hemoglobin A1c;
HDL = high density lipoprotein; LDL = low density lipoprotein; RCA = native right coronary artery; SVG-RCA = saphenous vein graft on right
coronary artery.
doi:10.1371/journal.pone.0124904.t001
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after stent implantation in RCA and SVG-RCA, but not different between groups (CD144+:
451.5±87.9 vs. 861.7±147.0 and 444.6±74.8 vs. 726.5±136.4 nr/μL; CD62E+: 1404.1±247.7 vs.
1844.3±378.6 and 1084.6±211.0 vs. 1783.8±384.3 nr/μL, P<0.05). The number of CD31+/
CD41- was not altered after stent implantation in both groups and not different between
groups (RCA: 77.1±17.6 vs. 80.4±27.0 nr/μL; SVG-RCA: 116.7±20.3 vs. 130.9±19.3 nr/μL,
P<0.05). The numbers of LMPs (CD45+) increased after stent implantation in RCA but not in
SVG-RCA (327.7±74.2 vs. 482.8±77.5 and 278.1±63.8 vs. 279.1±49.3 nr/μL). However, the dif-
ference did not reach statistical significance. The numbers of ERMPs (CD235+) were not al-
tered after stent implantation in both groups and not different between groups (317.3±64.7 vs.
324.0±56.6 and 256.6±43.3 vs. 254.2±43.2 nr/μL, P<0.05) (Fig 3).
Discussion
We here identified and compared the release of MPs into the coronary blood during stent im-
plantation into stable atherosclerotic lesions under protection with an occlusion/aspiration de-
vice. PMPs (CD41+), but also EMPs (CD144+ and CD62+) were released into RCAs and
Table 2. Angiographic characteristics of the lesion.
RCA SVG-RCA P-value
number 14 14 1.0
lesion with thrombus 0 0 1.0
quantitative coronary angiography
stenosis diameter [%] 63±3 60±4 0.6
IVUS-analysis
MLA [mm2] 2.9±0.1 4.0±0.5 0.03
RLA [mm2] 6.9±0.6 10.9±1.7 0.02
plaque burden [%] 68.1±2.4 64.9±2.9 0.4
stent
stent diameter [mm] 3.4±0.2 3.9±0.2 0.03
stent length [mm] 21.4±1.2 18.8±0.8 0.1
maximal balloon deployment pressure
pressure [atm] 19.7±0.9 20.3±0.9 0.6
Continuous data are presented as mean±SEM, categorical data as absolute numbers. Comparison between patients with RCA and with SVG-RCA by
unpaired t test (continuous data) and 2-tailed Fisher’s exact test (categorical data). IVUS = intravascular ultrasound; MLA = minimal lumen cross-sectional
area in the culprit segment; RCA = native right coronary artery; RLA = reference lumen area; SVG-RCA = saphenous vein graft on right coronary artery.
doi:10.1371/journal.pone.0124904.t002
Table 3. TIMI flow and serum troponin I before and after stent implantation.
RCA SVG-RCA
before after before after
stent implantation stent implantation
TIMI ﬂow n = 14 /14 2.9 ± 0.1 3.0* 2.8 ± 0.1 3.0*
troponin I [µg/L] n = 14 / 14 0.0 0.6 ± 0.4* 0.0 0.7 ± 0.3*
Data are mean±SEM. Comparison by 2-way repeated measures ANOVA with Bonferroni’s correction;
*P<0.05 before vs. after stent implantation. RCA = native right coronary arteries; SVG-RCA = saphenous vein grafts on right coronary arteries;
TIMI = thrombolysis in myocardial infarction.
doi:10.1371/journal.pone.0124904.t003
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SVG-RCAs during stenting of stable atherosclerotic lesions. However, there was no
difference between RCAs and SVG-RCAs. LMPs and ERMPs were not released during stent
implantation.
In prior studies, the MPs extracted from human atherosclerotic plaques were mainly derived
from activated leukocytes, erythrocytes and smooth muscle cells [20,21], whereas MPs in pe-
ripheral venous [37,38], systemic (arch of aorta) [24] and coronary blood [22,24,39] of patients
with stable CAD or STEMI were mainly derived from platelets and endothelial cells [39]. Me-
chanical stimuli can trigger the sequestration of MPs from atherosclerotic plaques [20,21], vas-
cular wall [38,40] and blood cells [39]. Stent implantation into the stable atherosclerotic lesion
of RCA or SVG-RCA induced mechanical plaque rupture, and released different amounts of
particulate debris. However, the numbers of MP released into RCA and SVG-RCA were com-
parable. Thus, MP release may not fully be explained as being a part of the particulate debris,
but rather the generation of MPs from platelets and endothelial cells. In the present study, we
confirmed prior reports by detecting a release of PMPs into the coronary blood of patients with
stent implantation into stable atherosclerotic lesion [24,39]. For the first time, we identified
also the release of EMPs into coronary blood after stenting a stable lesion, possibly as a result of
the use of a distal balloon occlusion/aspiration device during stent implantation, which pre-
vented the disappearance of MPs into the microcirculation. Numbers of LMPs increased after
stent implantation in RCA, but not in SVG-RCA. The difference did not reach statistical signif-
icance at this point and future studies with a large number of biological samples will have to
further address LMPs as a possible marker of the inflammatory response of stent implantation.
The precise molecular/biochemical trigger of MP generation from platelets and endothelial
cells has not been validated in vivo, yet. Ex vivo, cell activation and apoptosis induce MP release
by increasing intracellular calcium, loss in membrane lipid asymmetry, and cytoskeleton
Fig 1. RCA and SVG-RCA plaque volume (A) and composition (B) by IVUS VH analysis.Data are mean
±SEM, comparison by unpaired t-test. RCA = native right coronary arteries, SVG-RCA = saphenous vein
grafts on right coronary arteries.
doi:10.1371/journal.pone.0124904.g001
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protein reorganization [12,40,41]. The inflammatory mediator TNFα stimulates the generation
of EMPs in vitro from HUVEC after 24 h co-incubation [15]. Confirming our prior results [4],
TNFα was released into the coronary aspirate, probably reflecting the inflammatory status of
the vessel wall and promoting the generation and release of EMPs into the coronary aspirate in
vivo. PMP generation is induced by platelet activation during percutaneous coronary interven-
tion (PCI) [14,39]. Here, we detected PMP and EMP release during stent implantation of pa-
tients with stable CAD despite dual antiplatelet therapy. The dual antiplatelet therapy with
aspirin and clopidogrel inhibits ADP-induced platetet activation and aggregation [42]. Clopi-
dogrel is associated with decreased PMP and EMP numbers in patients with stable CAD
[43,44]. Thus, in the present study the dual antiplatelet therapy possibly reduced, but did not
prevented MP release.
Fig 2. Plasma concentration of TF, and number of TF-bearing MPs in RCA and SVG-RCA before and after stent implantation. Data are presented as
minimum and maximum (crosses), interquartile range from 25 to 75% (box), mean (square), and median (line) in a box plot. Comparison between arterial
plasma and aspirate plasma as well as RCA and SVG-RCA was done by 2-way repeated measures ANOVA followed by Fishers LSD post-hoc test;
MPs = microparticles, nr = number, RCA = native right coronary arteries, SVG-RCA = saphenous vein grafts on right coronary arteries, TF = tissue factor.
doi:10.1371/journal.pone.0124904.g002
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In patients with STEMI undergoing PCI in their native coronary arteries [25], the release of
MPs into coronary blood is accompanied by microvascular obstruction. PMPs promote throm-
bus generation [10] and might contribute to microvascular obstruction. In vivo- and in vitro-
generated isolated EMPs decrease the production of nitric oxide when incubated with rat aortic
rings ex vivo [45,46] and contribute to vasoconstriction. EMPs also promote inflammation in
the vascular wall by enhancing pro-inflammatory cytokine release or leukocyte adhesion and
migration [47]. MPs carry active TF and expose phospatidylserine on their surface, thus acti-
vating the coagulation cascade [48]. In animal studies, vascular injury induced by angioplasty
of a stable atherosclerotic plaque results in increased TF expression of the vascular wall [49]. In
patients with acute coronary syndromes, TF is released into the coronary blood [50]. In the
present study, we measured the effect of elective stent implantation on TF in coronary aspirate
of patients using two different methods: we determined TF-bearing MPs using FACS and mea-
sured the TF release into the aspirate using an immunometric assay kit. In both RCA and
SVG-RCA, neither TF-bearing MPs nor plasma TF were increased after stent implantation.
This is in line with previous studies demonstrating no increase of intracoronary plasma TF
Fig 3. Numbers of MPs in RCA and SVG-RCA before and after stent implantation. Numbers of PMPs (CD41+), EMPs (CD144+, CD62E+ or CD31+/
CD41-), LMPs (CD45+), and ERMPs (CD235+) are presented as minimum and maximum (crosses), interquartile range from 25 to 75% (box), mean (square),
and median (line) in a box plot. Comparison between arterial plasma and aspirate plasma as well as RCA and SVG-RCA was done by 2-way repeated
measures ANOVA followed by Fishers LSD post-hoc test; EMPs = endothelium-derived MPs, ERMPs = erythrocyte-derived MPs, LMPs = leukocyte-derived
MPs, MPs = microparticles, nr = number, PMPs = platelet-derived MPs, RCA = native right coronary arteries, SVG-RCA = saphenous vein grafts on right
coronary arteries.
doi:10.1371/journal.pone.0124904.g003
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level immediately after stent implantation in stable CAD [1,3,4,26,51,52] and in acute myocar-
dial infarction [22]. However, there is a delayed increase of TF in coronary sinus blood 24 h
after stent implantation [53], possibly secondary to immunological or inflammatory processes.
Independent of TF, MPs possess procoagulant activity [54].
Taken together, traumatic plaque rupture induced by stent implantation into stable athero-
sclerotic lesions triggers PMP and EMP release, which might contribute to microvascular ob-
struction after stent implantation. However, we were unable to analyze such microvascular
obstruction or systemic effects, as—by definition—we removed MPs using the protection de-
vice; accordingly, post-interventional troponin release was only modest.
From a clinical view, the higher amount of particulate debris release in SVG-RCA intervention
in our study may suggest a greater benefit of using protection filter device during intervention of
a SVG as compared to intervention of a native coronary artery. In contrast, the comparable re-
lease of MPs between RCA and SVG-RCA suggest that strategies to reduce the deleterious effects
of particulate debris and released MPs are likely to be equally important in both.
Study Limitations
Here, we identified MPs released during stent implantation. However, this is a descriptive char-
acterization of MP composition and their functional relevance remains unclear. Our study was
limited to a small number of male patients undergoing elective stent implantation into their
RCA or SVG-RCA, respectively, and requires prospective confirmation in larger cohorts. Fur-
thermore, such a small sample size impedes the definitive explanation of the findings. IVUS
VH has not been validated for use in SVG, and the lack of a clear interface between media and
adventitia in SVG makes vessel volume measurements more problematic than in native coro-
nary arteries [1]. The aspiration procedure of coronary blood before and after stent implanta-
tion might be an artificial trigger for MP formation and could have affected the measured MP
number. In the present study the number of ERMPs did not change after stent implantation,
possibly serving as a positive control. However, this control does not exclude artificial MP for-
mations from other blood cells. Non-ionic contrast medium could also have induced platelet
activation [55], and contributed to the PMPs count [39]. We did not confirm the MP release
into coronary blood using an alternative method like electron microscopy. Furthermore, we
did not use a parallel approach to characterize the MPs, e.g. PMPs with activation marker
CD62P.
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